European Journal of Rheumatology
Case based Review

Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm

1.

Department of Medicine, Yale School of Medicine, New Haven, CT, United States

2.

Section of Rheumatology, Allergy & Immunology, Department of Medicine, Yale School of Medicine, New Haven, CT, United States

3.

Section of Hematology, Department of Medicine, Yale School of Medicine, New Haven, CT, United States

Eur J Rheumatol 2022; 9: 215-216
DOI: 10.5152/eurjrheum.2022.21097
Read: 278 Downloads: 50 Published: 24 January 2022

Biologic disease-modifying agents (bDMARDs) are highly effective in controlling the symptoms of autoimmune rheumatic diseases. The decision on whether to continue bDMARDs following a cancer diagnosis can be challenging for patients and physicians. Here, we describe a case of a middle-aged male with ankylosing spondylitis who was controlled on infliximab (IFX) and found to have a myeloid neoplasm with Platelet-Derived Growth Factor Receptor Beta rearrangement. The patient was started on a tyrosine kinase inhibitor imatinib. Given its significant positive effect on patient’s quality of life, IFX was continued with a favorable outcome. This case highlights the importance of shared decisionmaking in balancing risks and benefits of immunosuppressants in appropriate cases of hematologic malignancy.

Cite this article as: Gupta A, Afinogenova Y, Podoltsev NA, Danve A. Concurrent use of tumor necrosis factor inhibitor and tyrosine kinase inhibitor in ankylosing spondylitis and myeloid neoplasm. Eur J Rheumatol. 2022;9(4):215-216.

Files
EISSN 2148-4279